Freshlook Color Enhancers
Navigation Links
Freshlook Color Enhancers
| Products | Freshlook Color Enhancers |
| Company | CIBA Vision |
| Item | Freshlook Color Enhancers |
| Features | Fresh lenses promote comfortable wear. Affordable enhancing colors. Easy to care for, easy to change colors. |
| Description | Enhances the eye color of light-eyed patients. |
| Info | CIBA Vision Customer Service: (678) 415-3937 Web site: http://www.cibavision.com |
Related medicine products :
1. Freshlook Colors
2. Freshlook Colorblends
3. Freshlook Dimensions
4. Freshlook Radiance
5. LAnthony New Color Test 100 Hue Test
6. Ishihara Color Test
7. Ishihara Color Blindness Test
8. Wildeyes X-Colors
9. Durasoft 2 Colorblends
10. Durasoft 2 Colors
11. Durasoft 2 Colors for Light Eyes
Breaking Medicine News(10 mins):Health News:MRI Partners with Natural Marketing Institute 2Health News:MRI Partners with Natural Marketing Institute 3Health News:MRI Partners with Natural Marketing Institute 4Health News:Definitive study confirms chemo benefit in postmenopausal breast cancer 2Health News:Definitive study confirms chemo benefit in postmenopausal breast cancer 3Health News:Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients 2Health News:Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients 3Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 2Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 3Health News:Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting 2
[1] MRI Partners with Natural Marketing Institute[0] Definitive study confirms chemo benefit in postmenopausal breast cancer[0] Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients [0] Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar [1] Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting
Other Medicine News:Health News:The Female Health Company Schedules First Quarter Conference Call for February 13, 2008 2Health News:Charles River Laboratories International Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Vitals.com 'Goes Red' for American Heart Month 2Health News:Vitals.com 'Goes Red' for American Heart Month 3Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 2Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 3Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 2Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 3Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 4
The Female Health Company Schedules First Quarter Conference Call for February 13, 2008Charles River Laboratories International Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIUVitals.com 'Goes Red' for American Heart MonthBonn scientists simulate dinosaur digestion in the labSentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 LicensesCVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Its Better to Give Than to Receive 55771 1Its Better to Give Than to Receive 55771 2Its Better to Give Than to Receive 55771 3Change in Seasons 3A Ideal Time to Review Healthy Aging Habits 55768 1Change in Seasons 3A Ideal Time to Review Healthy Aging Habits 55768 2Prostate Cancer Over Diagnosed 3A Study 55767 1Prostate Cancer Over Diagnosed 3A Study 55767 2Prostate Cancer Over Diagnosed 3A Study 55767 3
[0] Boston Scientific Announces Pricing of $2 Billion of Senior Notes[0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer[0] AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |